Bullish
Pfizer's Q2 2026 earnings beat expectations; stock near 52-week high.
Pfizer reported a 3% increase in Q2 2026 revenue, driven by strong performance in oncology and primary care portfolios. The company raised its full-year revenue guidance midpoint to $61.5 billion, reflecting confidence in its pipeline and non-COVID products. The stock is trading near a 52-week high, indicating positive market sentiment.
Key points
- Q2 2026 revenue of $15.03 billion, a 3% increase from the previous year.
- Raised full-year 2026 revenue guidance midpoint to $61.5 billion.
- Stock trading near 52-week high, reflecting positive market sentiment.
Sources
AI-generated from public news sources. Not financial advice.
